Company / Working Capital
Solid Biosciences Inc. Working Capital History
FY2018-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$197.1M
FY2022
5-year range
$68.0M / $199.0M
FY2018-FY2022
Trend
-0.9%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $134M to $197M over the past 2 years.
Based on SEC 10-K filings.
$197M in FY2022 with a 3-year CAGR of +42.6%.
Improved from $134M to $197M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- +42.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +42.6%, indicating consistent growth.
- In FY2022, working capital decreased 0.9% year-over-year.
- Peak working capital was recorded in FY2021.
- Lowest working capital in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score 1.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $197.1M | -0.9% |
| FY2021 | $199.0M | +48.1% |
| FY2020 | $134.4M | +97.6% |
| FY2019 | $68.0M | -41.4% |
| FY2018 | $116.2M | - |
As of FY2022 · SEC 10-K · Updated Jun 28, 2026